Skip to main content

Ignite logo 02

 

Findings from the genomics field have slowly started to find applications in clinical care. The field of “genomic medicine” could potentially improve patient health and treatment strategies or better predict the likelihood of disease.

The IGNITE demonstration projects, funded through the National Human Genome Research Institute (NHGRI), incorporate genomic information into the electronic medical record (EMR) and provides clinical decision support (CDS) for implementation of appropriate interventions or clinical advice. The sites work together to develop new methods and projects and disseminate their findings to the public. Dissemination of these methods and developing best practices for implementation is a key goal so that the information generated from the program will contribute to the growing knowledge base of using genomic information in patient care.

UNC has had a role in the first iteration of IGNITE and now the PPMH is excited to be a part of a second iteration. We are excited to collaborate again with IGNITE on their current and upcoming projects. Below is a list of institutions joining the Pharmacogenetics working group along with the gene–drug pairs they have implemented into their clinical practice.

University of Florida CYP2C19‐clopidogrel; CYP2D6‐codeine, tramadol; TPMT‐thiopurines; CYP2D6/CYP2C19‐SSRIs; CYP2C19‐PPIs; CYP2C19‐voriconazole (in development)
Vanderbilt University CYP2C19‐clopidogrel; SLCO1B1‐simvastatin; CYP2C9/VKORC1‐warfarin; CYP3A5‐tacrolimus; TPMT‐thiopurines
Indiana University CYP2C19‐clopidogrel, voriconazole, PPIs, citalopram; CYP2D6‐opioids, SSRIs, aripiprazole, atomoxetine; SLCO1B1‐simvastatin; CYP2C9/VKORC1/CYP4F2‐warfarin; CYP3A5‐tacrolimus; TPMT‐thiopurines; CYP2D6/CYP2C19‐TCAs; DPYD‐5‐fluorouracil, capecitabine, tegafur; G6PD‐rasburicase; ITPA‐thioguanine; CYP2B6‐efavirenz
Sanford Health CYP2C19‐clopidogrel; CYP2C9/VKORC1‐warfarin; CYP2D6/CYP2C19‐SSRIs, TCAs; CYP2D6‐opioids; CYP3A5‐tacrolimus; SLCO1B1‐simvastatin; TPMT‐thiopurines; DPYD‐capecitabine, fluorouracil, tegafur
University of Maryland CYP2C19‐clopidogrel
Mount Sinai CYP2C19‐clopidogrel; CYP2C9/VKORC1‐warfarin; SLCO1B1‐simvastatin; CYP2D6‐codeine, tramadol; CYP2D6/CYP2C19‐TCAs (in development); CYP2D6/SSRIs (in development)
Duke University SLCO1B1‐statins
University of North Carolina at Chapel Hill CYP2C19‐clopidogrel
Nemours Children’s Health System CYP2C19‐PPIs
University of Illinois at Chicago CYP2C19‐clopidogrel; CYP2C9/VKORC1‐warfarin
Mission Health System HLA‐B*1502‐carbamazepine
St. Luke’s Mountain States Tumor Institute DPYD‐fluorouracil, capecitabine; TPMT‐thiopurines
University of Pittsburgh CYP2C19‐clopidogrel
University of Pennsylvania CYP2C19‐clopidogrel
H. Lee Moffitt Cancer Center & Research Institute CYP2C19‐voriconazole; CYP2D6‐opioids; TPMT‐thiopurines
University of Alabama, Birmingham CYP2C19‐clopidogrel

 

For more information, visit the IGNITE Network project website.